Skip to main content
Download PDF

SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells

Cellular & Molecular Biology Letters volume 29, Article number: 80 (2024) Cite this article

Abstract

Background

Sodium-glucose transporter 2 (SGLT2) inhibitors (iSGLT2) are approved medications for type 2 diabetes. Recent studies indicate that iSGLT2 inhibit the growth of some cancer cells. However, the mechanism(s) remains to be fully elucidated.

Methods

The SGLT2 levels were determined in normal colon CCD 841 CoN and, HCT 116, HT-29, SW480 and LoVo colorectal cancer (CRC) cell lines by quantitative real-time PCR and western blot. The effect of iSGLT2 canagliflozin on cell proliferation was examined using CCK-8, as its role on CRC cells metabolism and tumorigenesis has been evaluated by XF HS Seahorse Bioanalyzer and flow cytometric analyses. Transient gene silencing experiments and analysis of protein–protein interaction network were conducted to evaluate the SGLT2 molecular targets in CRC cells.

Results

Data showed that the treatment with iSGLT2 (50 µM) for 72 h induced cell cycle arrest (p < 0.001), impaired glucose and energetic metabolism (p < 0.001), promoted apoptotic cell death and ER stress flowing into autophagy (p < 0.001) in HCT 116 and HT-29 cells. These cellular events were accompanied by sirtuin 3 (SIRT3) upregulation (p < 0.01), as also supported by SIRT3 transient silencing experiments resulting in the attenuation of the effects of iSGLT2 on the cellular metabolic/energetic alterations and the induction of programmed cell death. The identification and validation of dipeptidyl peptidase 4 (DPP4) as potential common target of SGLT2 and SIRT3 were also assessed.

Conclusions

These results deepened knowledge on the iSGLT2 contribution in limiting CRC tumorigenesis unveiling the SGLT2/SIRT3 axis in the cytotoxic mechanisms.

Graphical Abstract

Background

Sodium-glucose cotransporter 2 (SGLT2) is a critical glucose transporter overexpressed in different cancer models, leading to increased glucose uptake in mice and humans [1, 2]. SGLT2 has been found significantly expressed in lung cancer metastasis, pancreatic and prostate adenocarcinomas, high-grade glioblastoma patients, cisplatin-resistant hepatoblastoma, renal cell carcinoma and its increased expression is related to a poor prognosis and decreased overall survival rates [3,4,5,6,7]. Particularly, high glucose levels can directly promote cancer onset and development with different mechanisms, including hyperinsulinemia, inflammation and adipokines imbalance, as well as providing cancer cells with important metabolic substrates [8, 9]. In this scenario, the SGLT2 inhibitors (iSGLT2), canagliflozin, dapagliflozin, tofogliflozin and empagliflozin, have been increasingly studied, given their strong anti-hyperglycemic activity as well as their emerging anticancer effects [8, 10]. These drugs are used to treat patients with type 2 diabetes and chronic kidney disease, as well as to improve cardiac function and reduce the risk of cardiovascular events, including heart failure [11,12,13]. Treatment with iSGLT2 also results in weight loss, decreased high blood pressure, and ameliorated insulin resistance, lipid profiles, and visceral adiposity [14, 15]. Overall, iSGLT2 are considered pleiotropic drugs exerting multiple beneficial effects, thus being considered as anti-frailty agents [13]. Canagliflozin is an antidiabetic drug acting on proximal renal tubules, able to reduce glucose reabsorption and promote its excretion through the urinary system, without affecting intestinal glucose uptake by SGLT1 [16, 17]. As other iSGLT2, canagliflozin, besides the blood glucose decrease, has been described to have additional beneficial effects, such as reduction of atherosclerotic plaque formation and body weight in rodents and patients with or without type 2 diabetes [14, 18,19,20]. Growing evidence, in vitro and in vivo, suggested the anticancer effects iSGLT2 canagliflozin, by impairing cell motility and survival as well as exerting cancer specific cytotoxicity alone and combined with oncological drugs [9, 21, 22]. Above all, iSGLT2 could reduce cancer cells glucose uptake and strongly impair cancer specific cell metabolism [9, 23]. Indeed, cancer cells adapt their metabolism to address the requirements of rapid growth, determining oncogenesis and metastasis [24].

Metabolic alterations are particularly critical for the initiation and progression of colorectal cancer (CRC), the third most common neoplasia worldwide, causing 10% of cancer-related deaths in high-income countries and a survival rate from 50 to 93%, depending on the tumor stage [25, 26]. Glucose and redox-energetic pathways differ in CRC cells, since metabolic reprogramming is exploited to provide energy and support for aberrant cell division [27,28,29], and the enhanced cellular request for glucose can be related to the overexpression of glucose transporters [30]. However, the deepened comprehension of molecular pathways regulating metabolic reprogramming in CRC needs further elucidations. In this context, it is conceivable that SGLT2 modulation in cancer could open a promising field for targeted treatment through iSGLT2. In this context, canagliflozin targets AMP-activated protein kinase (AMPK) activation by complex I of the respiratory chain, inhibits lipid synthesis in mouse liver, promotes mitochondrial remodeling in adipocytes, reduces cell proliferation by impairing mitochondrial respiration in different tumor models, and counteracts renal fibrosis in chronic kidney disease by enhancing sirtuin 3 (SIRT3) expression [31,32,33,34,35,36]. To date the expression levels, function, and molecular targets of SGLT2 in CRC oncogenesis have not been ascertained. Mechanistically, the knowledge about SGLT2 involvement on glucose homeostasis and mitochondrion-related redox-energetic metabolism in CRC models is still limited, as well as the molecular pathways triggering cytotoxicity. To this end, the present study was designed to investigate the role of SGLT2 on CRC burden and to evaluate the biological effects of its inhibition with iSGLT2, canagliflozin.

Methods

Cell culture, treatments, and transfection

Human colon epithelial CCD 841 CoN (CRL-1790) and colorectal adenocarcinoma HCT 116 (CCL-247), HT-29 (HTB-38), SW480 (CCL-228) and LoVo (CCL-229) cells were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) and grown as previously reported [37]. The iSGLT2 solution, canagliflozin, was prepared as previously described [14]. Briefly, canagliflozin pills were chopped, dissolved in Hanks’ balanced salt solution (HBSS)-10 mM Hepes, homogenized in a Precellys system and centrifugated at 14,000 rpm for 5 min. The supernatant was collected and sterilized through a 0.22 µm Millipore filter. Treatments were performed by culturing cells in complete medium with increasing concentrations of iSGLT2 (0–100 µM) up to 72 h.

As for molecular experiments, cells were transfected with RNAifectin (Vehicle, Applied Biological Materials, Inc., Richmond, BC, Canada) by using 50 nM SIRT3 siRNA (SIRT3−, Applied Biological Materials, Inc., Richmond, BC, Canada) or control non-targeting siRNA (NT) in serum- and antibiotic-free medium, as previously reported [38]. After transfection, treatments with iSGLT2 were performed. Control cells (Ctr) were maintained in complete culture medium with the corresponding highest volume of HBSS-10 mM Hepes.

Cell viability and cytotoxicity

Cell counting Kit-8 and cytotoxicity LDH assays (Donjindo Molecular Technologies, Inc., Rockville, MD, USA) were used to evaluate cell viability and cytotoxicity, respectively, according to manufacturer’s indications. Absorbances were recorded by using the 680-microplate reader (Bio-Rad, Hercules, CA, USA) and results reported as %.

Cell cycle assessment

After treatment, trypsinized cells were stained with BD Cycletest Plus DNA Kit (BD Biosciences, San José, CA, USA), following manufacturer’s protocol. The intracellular DNA content was analyzed with a FACS CANTO II cytometer (BD Biosciences, San José, CA, USA) and FlowJo V10 software (FlowJo LLC, Ashland, OR, USA). At least 10,000 events were recorded for each sample.

Metabolic evaluation

Metabolic state was investigated by using Glucose Assay Kit-WST (Dojindo Molecular Technologies, Tokyo, Japan), Lactate Assay Kit-WST (Dojindo, Molecular Technologies, Tokyo, Japan), NAD/NADH Assay Kit-WST (Dojindo Molecular Technologies, Tokyo, Japan), GSSG/GSH quantification kit (Dojindo Molecular Technologies, Tokyo, Japan), and ATP kit (Abcam, Cambridge, UK), according to the supplier’s instructions and as already described [38, 39]. Specific absorbances were measured with a microplate reader model 680 (Bio-Rad, Hercules, CA, USA).

Oxidative state

Intracellular and mitochondrial ROS levels were detected by CellROX green (Invitrogen, Waltham, MA, USA) and MitoSOX red mitochondrial superoxide indicator (Invitrogen, Waltham, MA, USA), respectively. After treatments, staining was performed with 5 μM of each reagent in complete medium and 30 min incubation at 37 °C. Cells were washed with phosphate buffered saline (PBS) and then imaged on a fluorescence microscope EVOS M5000 (Thermo Scientific, Rockford, USA), while FACS CANTO II (BD Biosciences, San Jose, CA, USA) was used to record fluorescence. Data analyses were performed by FlowJo V10 software (FlowJo LLC, Ashland, OR, USA).

Apoptotic cell death

Apoptotic mechanism was evaluated with Annexin V apoptosis detection kit (BD Pharmigen, Franklin Lakes, NJ, USA), while caspase-3/7 activation assessed by NucView 488 caspase-3 substrate and annexin V dual apoptosis kit (Biotium, Fremont, CA, USA), as previously reported [38, 40, 41]. Briefly, cells were washed with PBS and incubated for 30 min in binding buffer 1 × containing 2 µL annexin V-FITC and 2 µL propidium iodide (PI) or 5 μL of Annexin V and 5 μL of 0.2 mM NucView 488 caspase-3 substrate for apoptosis and caspase-3/7 detection, respectively. Flow cytometric analyses were performed with FACS CANTO II (BD Biosciences, San Jose, CA, USA) recording at least 10,000 events and results evaluated by FlowJo V10 software (FlowJo LLC, Ashland, OR, USA).

Mitochondrial respiration

Respiration assay was assessed with the Seahorse MitoStress kit (Agilent Technologies, Santa Clara, CA, USA), as already described [39]. Cells were seeded in Seahorse assay microplate in growth medium or treatment. Culture medium was replaced by complete XF DMEM (Agilent Technologies, Santa Clara, CA, USA) before the detection of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) conducted by XF HS Seahorse Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Results were normalized to protein content.

SIRT3 activity and content

SIRT3 activity was estimated with SIRT3 fluorometric assay (Enzo Life, Farmingdale, NY, USA), as previously described [38]. Briefly, 50 µL of substrate was added to each well and plate incubated for 5 h, before the addition of 50 µL Developer and 2 mM of nicotinamide (NAM), to stop the reaction. The fluorescence (ex 360 nm and em 460 nm) was measured by Tecan Infinite 2000 Multiplate reader (Tecan, Männedorf, Switzerland). The content of SIRT3 in culture medium was assessed by Sirtuin 3 ELISA Kit (MyBioSource, San Diego, CA, USA), according to the manufacturer’s protocol, and 450 nm absorbance values recorded by a 680-plate reader (Bio-Rad, Hercules, CA, USA).

Quantitative real-time PCR

RNA isolation and quantitative RT-PCR were performed, as already reported [39], to detect SGLT2 and SIRT3 mRNA levels. The relative sirtuin and SGLT2 expression levels were determined by comparing the expression of SIRT3 or SGLT2 to that of GAPDH with the 2−ΔΔCt method, using the primer sequences reported in Table S1. Each reaction was performed in triplicate and results were expressed as the mean ± SD of n = 3 independent experiments.

ER-phagy detection

Acidic lysosomes and autophagy were detected by LysoTracker Red DND-99 (Invitrogen, Waltham, MA, USA) and Autophagy assay kit (Abcam, Cambridge, UK), respectively. As previously described [39, 42], cells were incubated at 37 °C for 30 min in the dark with 1 µM LysoTracker or 2 μL green reagent and 1 μL nuclear stain. The occurrence of ER stress was assessed by staining cells for 30 min with 1 µM ER-Tracker Blue-White DPX dye (Invitrogen, Waltham, MA, USA). Fluorescent images were captured by EVOS M5000 imaging system (Thermo Scientific, Rockford, USA), while fluorescent signals quantified by FACS CANTO II (BD Biosciences, San Jose, CA, USA). For each sample at least 10,000 events were collected and results analyzed by FlowJo V10 software (FlowJo LLC, Ashland, OR, USA).

Immunoblotting analysis

Protein lysis, homogenate resolving by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), nitrocellulose membrane transfer, and chemiluminescent analysis were performed as previously described [42, 43]. The following primary antibodies were used for western blotting detection: anti-sodium-glucose cotransporter-2 (SGLT2, 1:500, Abcam, Cambridge, UK), anti-sirtuin 3 (SIRT3, 1:500, Cell Signaling Technology, Danvers, MA, USA), anti-dipeptidyl peptidase-4 (DPP4, 1:500, Abcam, Cambridge, UK) anti-5' AMP-activated protein kinase alpha-1 (AMPK, 1:1000, Invitrogen, Waltham, Ma, USA), anti-phospho-AMPK (1:1000, Invitrogen, Waltham, Ma, USA), anti-C/EBP homologous protein (CHOP, 1:1000, Elabscience Biotechnology Inc., Houston, TX, USA), anti-protein kinase RNA-like ER kinase (PERK, 1:1000, Elabscience Biotechnology Inc., Houston, TX, USA), anti-activating transcription factor 6 (ATF6, 1:1000, Biorbyt, Cambridge, UK), anti-microtubule-associated protein 1 light chain 3B (LC3B, 1:1000, Abcam, Cambridge, UK), anti-actin (1:5000, Abcam, Cambridge, UK), and anti-α-tubulin (1:3000, Elabscience Biotechnology Inc., Houston, TX, USA).

Analysis of protein–protein interaction network

SGLT2 and SIRT3 interactions were firstly detected by UniProtKB (https://www.uniprot.org/uniprotkb/P31639/entry#interaction) and networks visualized by retrieving direct interactors from the String database version 11.5 (https://version-11-5.string-db.org/cgi/network?taskId=bsoCJQUptkCT&sessionId=b1DrF8N2TVND). The minimum required interaction score value between DDP4 (ENSP00000353731) and SGLT2 (ENSP00000327943) was 0.910, corresponding to highest confidence, in human species. Putative homologs mentioned together in other organisms display 0.043 as score value. Of contrary, none DDP4-SIRT3 network relationship was predicted by the interaction database.

Statistical analysis

Results were represented as mean ± SD. Graphs and statistical analysis, as Student t-test and one-way ANOVA with Tukey post hoc test, were performed using GraphPad Prism version 9.1.2 and differences considered statistically significant as p < 0.05.

Results

SGLT2 levels in CRC cells and iSGLT2-induced cytotoxicity

To investigate the role of glucose transporter SGLT2 in the metabolic pathways and tumorigenesis of CRC cells, firstly the SGLT2 mRNA and protein levels were determined in normal colon CCD 841 CoN and four CRC cell lines, HCT 116, HT-29, SW480 and LoVo (Fig. 1). The qRT-PCR analysis revealed that the expression levels of SGLT2 were higher in CRC cells (5.19 ± 0.82—in HCT 116, 4.69 ± 0.67—in HT-29, 5.84 ± 1.18—in SW480 and 5.28 ± 0.77-fold change in LoVo) compared to normal CCD 841 CoN cells (0.99 ± 0.17-fold change, p < 0.01) (Fig. 1A). A similar trend was observed for SGLT2 protein levels (p < 0.01) (Fig. 1B).

Fig. 1
figure 1

SGLT2 levels and iSGLT2-mediated cytotoxicity in CRC. Basal SGLT2 (A) mRNA expression, measured by qRT-PCR, and (B) protein levels, detected by immunoblotting, in CCD 841 CoN, HCT 116, HT-29, SW480, and LoVo cells. M = molecular weight markers, lane 1 = CCD 841 CoN, lane 2 = HCT 116, lane 3 = HT-29, lane 4 = SW480, lane 5 = LoVo. Western blotting is expressed as arbitrary units (AU), mRNA levels are reported as floating bars with a line representing the median ± SD of n = 3 independent experiments. ¶p < 0.01 vs. CCD 841 CoN. Cell viability and cytotoxicity evaluated in (C, D) HCT 116 and (E, F) HT-29 cells treated with iSGLT2 (0–100 µM) for 24, 48 and 72 h. Representative cell cycle detection by cytometric analysis in (G, H) HCT 116 and (I, J) HT-29 cells exposed to 50 µM iSGLT2 for 72 h (iSGLT2). Control cells (0 or Ctr) were maintained in complete culture medium with the corresponding highest volume of HBSS-10 mM Hepes. The data are expressed as the mean ± SD of n = 3 independent experiments. *p < 0.05 vs. 0 µM or Ctr; †p < 0.01 vs. 0 µM or Ctr; ‡p < 0.001 vs. 0 µM or Ctr by unpaired Student’s t-test

Full size image

To further evaluate the functional involvement of SGLT2, canagliflozin, the iSGLT2 used in the present study from now on referred to as iSGLT2, was tested on cell viability, by measuring the NADH in living cells and cytotoxicity, by measuring the release of LDH from dead cells (Fig. 1 and Fig. S1). Dose–response experiments indicated that 10 µM and 25 µM iSGLT2 treatment poorly reduced HCT 116 and HT-29 cell viability (88.95 ± 6.31 and 85.78 ± 3.39, p < 0.05; 74.09 ± 9.42 and 72.45 ± 3.91, p < 0.01), while less pronounced reduction was observed in SW480 and LoVo cell (Fig. 1 and Fig. S1). When treated with 50 µM iSGLT2, SW480 and LoVo cells increased their reduction of cell viability (71.28 ± 9.6 and 78.78 ± 5.5, p < 0.01 and p < 0.05) (Fig. S1A,C), while 50 µM iSGLT2 was the lowest effective concentration able to impair HCT 116 and HT-29 cell viability about 50% (55.86% ± 4.39 and 57.78% ± 4.98, p < 0.001) and induce the highest cytotoxic effects after 72 h of treatment (24.96% ± 2.59 and 25.21% ± 2.94, p < 0.001) (Fig. 1C–F), suggesting the higher responsiveness and sensibility of HCT 116 and HT-29 cells to iSGLT2 treatment, compared to SW480 and LoVo cell lines.

Moreover, the incubation with iSGLT2 at the highest dose (100 µM) was able to heavily decrease HCT 116 and HT-29 cell viability (35.7 ± 9.4 and 52.5 ± 6.04, p < 0.001) (Fig. 1C, E) and aggravate the SW480 and LoVo cell viability reduction (62.75% ± 6.79 and 70.25% ± 6.91, p < 0.01) and cytotoxicity (21.27% ± 4.76 and 22.12% ± 2.36, p < 0.01) (Fig. S1A–D), furtherly underlining the higher HCT 116 and HT-29 cell susceptibility to iSGLT2 treatment. In contrast, non-malignant CCD 841 CoN cells were not affected by iSGLT2 treatment (Fig. S1E), suggesting that the SGLT2 inhibitor was specific to tumor cells.

Based on this results, the iSGLT2 concentration of 50 µM was chosen to conduct the experiments of the present study on HCT 116 and HT-29 cells.

When cell cycle analysis was performed, iSGLT2 induced the arrest in S phase arrest in HCT 116 (56.94% ± 2.62 vs. 39.39% ± 2.40 of Ctr, p < 0.001) and HT-29 cells (38.19% ± 2.84 vs. 28.06% ± 1.90 of Ctr, p < 0.01) (Fig. 1G–J).

In conclusion, treatment with iSGLT2 was able to specifically decrease CRC cell viability, induce cytotoxicity and promote cell cycle arrest in HCT 116 and HT-29 cells.

iSGLT2 effects on glucose metabolism

The effects of SGLT2 inhibition on glucose metabolism was then evaluated (Fig. 2 and Fig. S2). Exposure to iSGLT2 resulted in decreased glucose and lactate content, as well as ATP production and NAD+/NADH ratio in HCT 116 cells (p < 0.001) (Fig. 2A–D). These effects were accompanied by increased AMPK protein expression (p < 0.01), as evidenced by the evaluation of its total and phosphorylated levels and by phosphorylated/total ratio in iSGLT2-treated cells (Fig. 2E–G). Similarly, in HT-29 cells, treatment with iSGLT2 impaired glucose, lactate ATP levels and NAD+/NADH ratio (p < 0.01), while enhancing AMPK expression (p < 0.05) (Fig. S2).

Fig. 2
figure 2

iSGLT2 affects glucose metabolism in CRC. Evaluation of (A) glucose, (B) lactate, (C) ATP and (D) NAD+/NADH levels and immunoblotting analysis with cropped blots of (E) AMPK, (F) p-AMPK and (G) p-AMPK/AMPK ratio in HCT 116 cells treated with 50 µM iSGLT2 for 72 h (iSGLT2). Control cells (Ctr) were maintained in complete culture medium with the corresponding volume of HBSS-10 mM Hepes. M = molecular weight markers, lane 1 = Ctr, lane 2 = iSGLT2. Western blotting results are expressed as arbitrary units (AU). *p < 0.05 vs. Ctr; †p < 0.01 vs. Ctr; ‡p < 0.001 vs. Ctr, by unpaired Student’s t-test

Full size image

Overall, iSGLT2 treatment affected glucose metabolism, by decreasing glucose and lactate content, ATP production, NAD + /NADH ratio and increasing AMPK protein expression in CRC cells.

iSGLT2 causes mitochondrion-mediated oxidative stress and apoptosis

To investigate the SGLT2 inhibition-mediated cytotoxicity, oxidative state and apoptotic cell death were explored under iSGLT2 exposure (Fig. 3 and Fig. S3). The content of intracellular and mitochondrial reactive oxygen species (ROS) during iSGLT2 treatment showed an extensive accrual of reactive species in both cellular compartments of HCT 116 cells (p < 0.001) (Fig. 3A–D and Fig. S3A, B). Exposure to iSGLT2 decreased live cells (68.3% ± 4.72 vs. 93.6% ± 3.02 in Ctr, p < 0.001), induced late apoptotic accumulation (23.5% ± 4.20 vs. 3.07% ± 0.84 in Ctr, p < 0.001) (Fig. 3E, F) and caspase-3 activation (p < 0.001) (Fig. 3G and Fig. S3C). Likewise, iSGLT2 mediated intracellular and mitochondrial ROS generation (p < 0.001), live cell reduction (72.9% ± 3.31 vs. 93.1% ± 2.91 in Ctr, p < 0.001) with late apoptotic rate increase (18.0% ± 1.94 vs. 3.94% ± 0.84 in Ctr, p < 0.01) and caspase-3 activation (p < 0.01) in HT-29 cells (Fig. 3H–N and Fig. S3D–F).

Fig. 3
figure 3

iSGLT2 causes mitochondrion-mediated oxidative stress and apoptosis in CRC. Representative fluorescent images and cytofluorimetric detection of (A, B and H, I) intracellular and (C, D and J, K) mitochondrial ROS levels, and dot plots and analyses of (E, F and L, M) annexin V-FITC and propidium iodide (PI)-staining and (G, N) detection of caspase-3/7 activation in HCT 116 and HT-29 cells treated with 50 µM iSGLT2 for 72 h (iSGLT2). Control cells (Ctr) were maintained in complete culture medium with the corresponding volume of HBSS-10 mM Hepes. Scale bars = 100 µm. Lower left quadrant: viable cells; upper left quadrant: necrotic cells; lower right quadrant: early apoptotic cells; upper right quadrant: late apoptotic cells. *p < 0.05 vs. Ctr; †p < 0.01 vs. Ctr; ‡p < 0.001 vs. Ctr, by unpaired Student’s t-test

Full size image

Comprehensively, iSGLT2 treatment promoted oxidative stress and induced apoptosis of CRC cells via caspase 3 activation.

iSGLT2 impairs energetic state and modulates SIRT3

Evidence on oxidative stress and apoptotic pathway led to further investigate the role of SGLT2 in mitochondrion cytotoxicity by evaluating mitochondrial respiration and glycolytic state (Fig. 4 and Fig. S4 and Fig. S5). In HCT 116 cells, treatment with iSGLT2 decreased the GSH/GSSG ratio (p < 0.01), along with ATP-production coupled respiration (p < 0.001), maximal and basal respiration (p < 0.01), and the percentage of coupling efficiency (p < 0.001) (Fig. 4A–E and Fig. S4A, B). Given the major role of SIRT3 in the regulation of cancer metabolism and mitochondrial homeostasis, its levels under iSGLT2 treatment in CRC cells were evaluated [44]. Results showed that the iSGLT2-mediated mitochondrial injury led to the upregulation of SIRT3 activity (p < 0.01) as well as mRNA and protein levels (p < 0.01) (Fig. 4F–I). These results were confirmed also in HT-29 cell line (Figs. S4 and S5).

Fig. 4
figure 4

iSGLT2 impairs energetic state and modulates SIRT3 levels in CRC. Evaluation of (A) GSH/GSSG ratio and (B) ATP production coupled respiration, (C) maximal and (D) basal respiration, and (E) coupling efficiency assessed by Seahorse analyzer and (F) SIRT3 activity, (G) content evaluated by ELISA kit, (H) mRNA expression and (I) immunoblotting analysis with cropped blots in HCT 116 cells treated with 50 µM iSGLT2 for 72 h (iSGLT2). Control cells (Ctr) were maintained in complete culture medium with the corresponding volume of HBSS-10 mM Hepes. M = molecular weight markers, lane 1 = Ctr, lane 2 = iSGLT2. Western blotting is expressed as arbitrary units (AU), mRNA levels are reported as floating bars with a line representing the median ± SD of n = 3 independent experiments. †p < 0.01 vs. Ctr; ‡p < 0.001 vs. Ctr, by unpaired Student’s t-test

Full size image

Overall, treatment of CRC cells with iSGLT2 decreased GSH/GSSG ratio, impaired mitochondrial respiration and increased SIRT3 protein levels and activity.

iSGLT2 triggers ER stress and autophagic flux

The crosstalk between mitochondrial function and autophagy, both part of the global endoplasmic reticulum (ER) stress response [45], prompted to explore the occurrence of autophagy and ER stress under SGLT2 inhibition (Fig. 5 and Figs. S6, S7). These two phenomena were assessed by evaluating the protein expression levels of autophagy marker, LC3B II/I, and ER stress markers, PERK, CHOP and ATF6. In HCT 116 cells, results showed that iSGLT2 triggered lysosome accumulation (p < 0.001) associated to autophagic mechanism (p < 0.001) via LC3B II/I upregulation (p < 0.01) (Fig. 5A–E and Fig. S6A, B). These phenomena were accompanied by ER stress (p < 0.01) sustained by upregulated PERK, CHOP and ATF6 protein levels (p < 0.01) (Fig. 5F–J and Fig. S6C). Similarly, in HT-29 cells, iSGLT2 induced lysosome accumulation (p < 0.001), LC3B II/I-related autophagy (p < 0.001) and ER stress (p < 0.01) mediated by increased PERK, CHOP and ATF6 protein expression (p < 0.01) (Fig. S6D–F and Fig. S7).

Fig. 5
figure 5

iSGLT2 promotes autophagic flux and ER stress in CRC. Representative fluorescent images and cytofluorimetric detection of (A, B) lysosomes, (C,D) autophagy and (E) immunoblotting analysis with cropped blots of LC3B II/I ratio in HCT 116 cell lines. Representative fluorescent images and cytofluorimetric detection of (F, G) ER stress and immunoblotting analysis with cropped blots of (H) PERK, (I) CHOP and (J) ATF6 protein levels in HCT 116 cells treated with 50 µM iSGLT2 for 72 h (iSGLT2). Control cells (Ctr) were maintained in complete culture medium with the corresponding volume of HBSS-10 mM Hepes. Scale bars = 100 µm. M = molecular weight markers, lane 1 = Ctr, lane 2 = iSGLT2. Western blotting results are expressed as arbitrary units (AU). *p < 0.05 vs. Ctr; †p < 0.01 vs. Ctr; ‡p < 0.001 vs. Ctr, by unpaired Student’s t-test

Full size image

In conclusion, iSGLT2 treatment provoked autophagy via LC3B II/I upregulation, induced ER stress via upregulation of PERK, CHOP and ATF6 protein levels, in CRC cells.

siSIRT3 opposes iSGLT2-dependent cytotoxicity and mitochondrial injury

Given the results on SIRT3 modulation and taking into account the debatable role played by this sirtuin in CRC carcinogenesis [37, 42, 46,47,48], the effects of SIRT3 silencing (siSIRT3) during iSGLT2 treatment were explored (Fig. 6 and Fig. S8). Results showed that SIRT3 downregulation opposed the iSGLT2-mediated cytotoxicity but only partially since never reached the control conditions (p < 0.01 vs. NT + iSGLT2), as well as the reduction of glucose, lactate, ATP and NAD+/NADH content in HCT 116 cells (p < 0.01 vs. NT + iSGLT2) (Fig. 6A–E). SIRT3 silenced cells also revealed a decreased mitochondrial ROS amount compared to NT + iSGLT2 treatment (p < 0.01) (Fig. 6F, G and Fig. S8). In addition, siSIRT3 alone yielded no different effects compared to the control cells. Similar results were observed in HT-29 cells. Indeed, SIRT3 inhibition attenuated the iSGLT2-related cytotoxicity (p < 0.01 vs. NT + iSGLT2), counteracted the impaired glucose, lactate, ATP and NAD+/NADH levels (p < 0.05 vs. NT + iSGLT2), as mitochondrial ROS generation (p < 0.01 vs. NT + iSGLT2) (Fig. 6H–N and Fig. S8). In summary, transient SIRT3 gene silencing opposed iSGLT2-induced cytotoxicity, metabolic and redox alteration in CRC cells.

Fig. 6
figure 6

siSIRT3 opposes iSGLT2-dependent cytotoxicity and mitochondrial injury. Detection of (A, H) cytotoxicity, (B, I) glucose, (C, J) lactate (D, K) ATP and (E, L) NAD+/NADH levels and cytofluorimetric detection and representative fluorescent images of (F, G and M, N) mitochondrial ROS in HCT 116 and HT-29 cells treated with 50 µM iSGLT2 for 72 h (iSGLT2) or transfected with nontargeting siRNA control (NT) or SIRT3 siRNA (siSIRT3) before exposure to iSGLT2 (NT + iSGLT2 or siSIRT3 + iSGLT2). Control cells (Ctr) were maintained in complete culture medium with the corresponding volume of HBSS-10 mM Hepes. Scale bars = 100 µm. †p < 0.01 vs. Ctr; ‡p < 0.001 vs. Ctr; *p < 0.01 vs. NT; ¶p < 0.001 vs. NT; •p < 0.05 vs. NT + iSGLT2; §p < 0.01 vs. NT + iSGLT2. Significance was determined using one-way ANOVA with Tukey post hoc test

Full size image

siSIRT3 counteracts cell death mechanisms induced by iSGLT2

Transient SIRT3 deprivation opposed the iSGLT2-related cell death mechanisms in HCT 116 and HT-29 cells (Fig. 7 and Fig. S9). Results showed attenuated autophagy (p < 0.01 vs. NT + iSGLT2), apoptosis (p < 0.05 vs. NT + iSGLT2) and ER stress (p < 0.01 vs. NT + iSGLT2) when SIRT3 was silenced in HCT 116 cells under iSGLT2 exposure (Fig. 7A–E and Fig. S9A–C). Likewise, in HT-29 results showed decreased rate of autophagy (p < 0.01 vs. NT + iSGLT2), apoptotic cell death (p < 0.01 vs. NT + iSGLT2) and ER stress (p < 0.05 vs. NT + iSGLT2) in siSIRT3 + iSGLT2 cells (Fig. 7F–J and Fig. S9D–F). Overall, silencing of SIRT3 opposed iSGLT2-induced apoptosis, autophagy and ER stress.

Fig. 7
figure 7

siSIRT3 counteracts cell death mechanisms induced by iSGLT2. Representative cytofluorimetric detection and fluorescent images of (A, B and F, G) autophagy, (C, H) analysis of annexin V-FITC and propidium iodide (PI)-staining and (D, E and I, J) ER stress in HCT 116 and HT-29 cells treated with 50 µM iSGLT2 for 72 h (iSGLT2) or transfected with nontargeting siRNA control (NT) or SIRT3 siRNA (siSIRT3) before exposure to iSGLT2 (NT + iSGLT2 or siSIRT3 + iSGLT2). Control cells (Ctr) were maintained in complete culture medium with the corresponding volume of HBSS-10 mM Hepes. Scale bars = 100 µm. †p < 0.01 vs. Ctr; ‡p < 0.001 vs. Ctr; *p < 0.01 vs. NT; ¶p < 0.001 vs. NT; •p < 0.05 vs. NT + iSGLT2; §p < 0.01 vs. NT + iSGLT2. Significance was determined using one-way ANOVA with Tukey post hoc test

Full size image

DPP4 as a common target of SGLT2 and SIRT3

The ability of SIRT3 silencing to counteract the iSGLT2-mediated mechanisms, prompted further studies elucidating a possible SGLT2/SIRT3 common target. Analyses by protein–protein interaction databases evidenced dipeptidyl peptidase 4 (DPP4) as direct target of SGLT2 with high confidence score (Fig. 8A), whilst no interaction was found with SIRT3, although recent evidence described a SIRT3-DPP4 interaction [49]. Moreover, recent evidence has shown that DPP4 promotes the development, progression and metastasis of CRC, making it a potential and novel therapeutic target for CRC [50]. To this end, to investigate the SGLT2 and SIRT3 capacity to modulate DPP4 protein levels, immunoblotting analysis with both iSGLT2 and SIRT3 silencing was performed (Fig. 8B,C). Treatment with iSGLT2 led to downregulated DPP4 protein levels (p < 0.01 vs. Ctr and NT). SIRT3 deprivation increased the peptidase expression in HCT 116 and HT-29 cells (Fig. 8B,C) (p < 0.01 vs. NT). Compared to SIRT3−, the siSIRT3 + iSGLT2 slightly decreased DPP4 protein levels only in HT-29 cells (p = 0.044), while no difference were observed in HCT 116 cells (p = 0.056). Of contrary, the siSIRT3 + iSGLT2 cells showed higher DPP4 protein levels compared to iSGLT2 treatment (p < 0.01), suggesting a more pronounced modulating effect exerted by SIRT3 silencing (Fig. 8B,C).

Fig. 8
figure 8

DPP4 as a target of SGLT2 and SIRT3. A SIRT3 (left) and SGLT2 (as SLC5A2, right) full interaction networks estimated on STRING database (https://string-db.org/) with the following setting parameters: minimum required interaction score: 0.400; max number of interactors to show in the first shell: 10, and none for the second shell. The dotted line suggests the potential interaction between SIRT3 and DPP4. B, C Immunoblotting analysis with cropped blots of DPP4 protein levels in HCT 116 and HT-29 cells treated with 50 µM iSGLT2 for 72 h (iSGLT2) or transfected with nontargeting siRNA control (NT) or SIRT3 siRNA (siSIRT3) before exposure to iSGLT2 (NT + iSGLT2 or siSIRT3 + iSGLT2). Control cells (Ctr) were maintained in complete culture medium with the corresponding volume of HBSS-10 mM Hepes. M: molecular weight markers; lane 1: Ctr; lane 2: iSGLT2; lane 3: NT; lane 4: NT + iSGLT2; lane 5: SIRT3−; lane 6: siSIRT3 + iSGLT2. †p < 0.01 vs. Ctr; *p < 0.01 vs. NT; §p < 0.01 vs. NT + iSGLT2. Significance was determined using one-way ANOVA with Tukey post hoc test

Full size image

In conclusion, treatment with iSGLT2 induced a downregulation of DPP4 protein levels, whereas silencing of SIRT3 induced an increase in DPP4 protein levels, suggesting a new signaling network in CRC cells.

Discussion

This study shows first evidence on the role of glucose transporter SGLT2 in CRC cells, as demonstrated by the cytotoxic effect of iSGLT2, canagliflozin, via impaired glucose metabolism and mitochondrial bioenergetic injury. The iSGLT2-mediated metabolic alterations were accompanied by SIRT3 upregulation, cell cycle arrest, apoptotic cell death, autophagy and ER stress occurrence in CRC cells. Moreover, SIRT3 deprivation reduced the iSGLT2-related cytotoxicity, metabolic and mitochondrial damage, and the induction of cell death mechanisms. Analysis by protein–protein interaction database unveiled dipeptidyl peptidase 4 (DPP4) as SGLT2 molecular target. Immunoblotting detection confirmed the DPP4-SGLT2 interplay and, of note, provided the first evidence of a DPP4 modulation exerted by SIRT3.

Aberrant proliferation and aggressiveness of cancer are related to alterations in metabolic parameters. Glucose metabolism usually is deregulated through the different oncogenic stages of CRC progression and is associated to suppression of immune cells [5, 24]. Metabolic reprogramming has been recognized as one of the main mechanisms sustaining CRC initiation and development, thus, it is conceivable that metabolic impairment, negatively impacting tumor onset, might represent a milestone for innovative anticancer strategies [27,28,29, 37]. It is well-reported that several cancer cells express the glucose transporter SGLT2, being strictly dependent on glucose utilization for growth and proliferation [4, 7]. SGLT2 has been also described as diagnostic marker and therapeutic target in tumor [51], although many mechanistic aspects remain undebated, as its role in CRC development. Consistent with previous data showing upregulated SGLT2 expression in several cancer models and its association to metastasis, drug resistance, poor prognosis and survival, here, we found increased SGLT2 mRNA and protein levels in CRC cells compared to non-tumor cells [3,4,5,6,7]. In this context, accumulating evidence described the in vitro and in vivo anticancer activity of iSGLT2 as well as its synergistic effects when combined with chemotherapy and radiotherapy [5, 52]. In prostate and lung cancer cells iSGLT2 reduced proliferation and clonogenic survival, alone and in combination with docetaxel and ionizing radiation [33]. Treatment with iSGLT2 opposed glucose uptake and cisplatin resistance in hepatoblastoma cells [6], triggered apoptosis and abrogated breast cancer stemness via miR-128-3p overexpression [53, 54]. Canagliflozin re-sensitized hepatocellular carcinoma to cisplatin by inducing ferroptosis [55], regulated glycolysis and glutamine metabolism, inhibited proliferation and clonogenic survival and enhanced radiotherapy efficacy by suppressing mitochondrial oxidative phosphorylation in non-small cell lung cancer [35]. In CRC patients, treatment with iSGLT2 counteracted cell growth, development and adhesion, and displayed synergic interaction with cetuximab [33, 56,57,58,59]. Results of this study showed the ability of canagliflozin to decrease CRC cell viability and induce cytotoxicity, with higher effects in HCT 116 and HT-29 cells, consistent with previous in vitro and in vivo data describing the iSGLT2-mediated inhibition of tumor growth and development [33, 56, 58, 59]. It is conceivable to speculate that the lower iSGLT2-related cytotoxicity in SW480 and LoVo cells might reflect the involvement of other SGLT2-independent metabolic targets responsible of tumor development, suggesting different responsiveness among CRC cells.

The iSGLT2 canagliflozin-mediated cytotoxicity has been related to cell cycle arrest in G1 or G1/S phase and apoptotic cell death via caspase-3 activation in hepatocellular carcinoma and lung and thyroid cancer cells [60,61,62]. Likewise, the results of this study provided the first evidence that iSGLT2 treatment triggered S-phase cell cycle arrest and caspase-3-dependent apoptotic cell death in HCT 116 and HT-29 cells. In line with recent reports, SGLT2 inhibition suppressed glucose uptake, lactate release, ATP production and increased AMPK activation, opposing signaling pathways which contribute to metabolic reprogramming and tumor progression [34, 35, 63]. AMPK is generally phosphorylated to decrease energy consumption and restore energetic metabolism when ATP synthesis is impaired or its consumption is accelerated [64]. Phosphorylated AMPK downregulates many key anabolic enzymes while promoting ATP production, regulating lipid and glucose metabolism, autophagy and inhibiting tumor growth [65]. Rapid activation of AMPK is a cell response to energetic stress and mitochondrial poisons [66]. In this study, we found that iSGLT2 treatment induced oxidative stress, inhibited GSH/GSSG ratio and mitochondrial respiration in CRC HCT 116 and HT-29 cells, as reported in prostate and lung cancer [33,34,35]. We found that iSGLT2 promoted lysosome accumulation and autophagy cell death via LC3B activation in CRC cells and along with ER stress induction and upregulation of the molecular players related to autophagy triggered by ER stress, namely ER-phagy, i.e., PERK, CHOP and ATF6 [45, 67, 68]. Several reports described the ER stress-mediated autophagy-associated cell death as antitumor strategies in CRC [39, 69,70,71]. However, to date no studies explored the association between SGLT2 and ER stress/autophagy as antineoplastic tool in CRC. In HCT 116 and HT-29 the iSGLT2-induced ER-phagy cell death mechanism was also accompanied by SIRT3 upregulation. Increasing evidence closely relate SIRT3 to clinical outcomes of CRC, acting as a tumor promoter or suppressor [40, 72,73,74].

In cancer, SIRT3 targets different enzymes regulating oxidative stress and cell metabolism [75, 76] thus acting as a tumoral promoter, by maintaining ROS content under specific thresholds, or tumor suppressor by triggering cell death under stress conditions [77]. SIRT3 is highly expressed in CRC cells leading to tumor resistance and poor overall survival [78, 79], with the reduction of protein expression resulting in cytotoxicity, cell death and impaired metabolic state and aggressiveness [42, 74]. Of contrary, other studies described a low expression of SIRT3 as predicting poor prognosis in CRC patients and its upregulation related to metabolic reprogramming and cell death mechanisms in in vitro models [37, 46, 47]. Increased SIRT3 activity and expression resulted in altered mitochondrial activity via ROS generation, loss of mitochondrial membrane potential, metabolic reprogramming, apoptosis and necroptotic cell deaths in CRC cells [37, 46, 80]. Studies showed the capacity of empagliflozin to protect heart from doxorubicin cardiomyopathy in mice by enhancing Beclin-1/ toll-like receptor (TLR)9/ SIRT3 axis and the effects of empagliflozin and canagliflozin to ameliorate renal injury by rescuing SIRT3 expression and limiting aberrant glycolysis, oxidative stress, and epithelial-mesenchymal transition (EMT) [36, 81, 82]. In accordance, results of this study showed that treatment with canagliflozin upregulated SIRT3 mRNA and protein levels, and increased content and activity of SIRT3 in HCT 116 and HT-29 cells. At molecular level, transient silencing experiments revealed that SIRT3 deficiency opposed the canagliflozin-mediated cytotoxicity, metabolic alterations and cell death mechanisms, thus reporting the first evidence of SGLT2/SIRT3 interaction in CRC.

Further investigations suggested DPP4 as a downstream target of SGLT2 and SIRT3, as revealed by the ability of both SGLT2 inhibition and SIRT3 silencing to modulate the peptidase protein levels in HCT 116 and HT-29 cells. Recent evidence described the crucial role of DPP4 in CRC initiation and progression and demonstrated the association of DPP4-inhibitor treatment with a better prognosis of CRC patients [50, 83]. The correlation of SGLT2/SIRT3 with DDP4 regulation has been independently described, although in different experimental models [49, 84]. Treatment with the iSGLT2 dapagliflozin reduced DPP4 serum levels in patients with type 2 diabetes and non-alcoholic fatty liver disease [85], while the DPP4 inhibitor sitagliptin ameliorated the ischemia/reperfusion-induced injury in cardiomyocytes by mediating SIRT3 upregulation and autophagy [49]. In accordance, our results revealed a negative DPP4 regulation under iSGLT2 exposure, with a significant peptidase overexpression when SIRT3 was silenced, suggesting DPP4 as a novel molecular target of SGLT2 and unveiling its value as therapeutic tool in CRC.

Despite significant improvements in diagnosis and therapeutic approaches, CRC management is not yet at a satisfactory level since the mortality rate increases globally over the years and a better understanding of underlying molecular mechanisms is needed to find new effective agents for CRC treatment [85]. Screening programs and novel surgical techniques allowed a reduction of CRC mortality rates in non-metastatic patients, although about 22% of CRC-related deaths have metastasis which cannot be surgically treated and therefore treatment with conventional chemotherapies represents the only option [86, 87]. To date, metastasis is the leading mortality cause in CRC patients [25, 26, 88]. In this context, search of new targets for precision therapeutics and innovative agents to overcome traditional medicine limits are compelling necessities. The present study unveils a crucial role of iSGLT2 in glucose metabolism and metabolic energetic reprogramming in CRC tumorigenesis, suggesting a dynamic interplay among metabolic alteration, damaged mitochondrial bioenergetic machinery, and the induction of programmed cell death mechanisms in response to SGLT2 suppression. A mechanistic approach unveiled the SGLT2-SIRT3 interaction and deepened molecular targets involved in SGLT2-mediated antineoplastic effects.

Conclusions

Altogether, these findings, adding knowledge on SGLT2 role in cancer development and progression, support its potential as crucial target in CRC treatment. Undoubtedly, other roles of SGLT2 in the development and prognosis of CRC warrant further investigation. It is undeniable that other regulators and pathways may be involved in SGLT2-mediated cytotoxicity. Further studies to pinpoint additional processes through which SGLT2 modulates CRC viability and to better understand how SGLT2 affects SIRT3 activity and levels are compelling. In addition, validating results in preclinical tumor models are required to overcome differences due to different susceptibilities proper of each cellular model used for the study. Indeed, the mechanisms provided by this study will be of great interest in the field, hopefully providing bases to new future clinical applications of iSGLT2. Nonetheless, important issues still need to be clarified before hypothesizing an in human application. Firstly, the effects evaluated in vitro are the result of cells exposure to high drug dosages, which would imply high drug site-specific accumulation in vivo to obtain the same effect. Also, the in vitro drug concentrations are often higher than the maximum drug blood serum concentration reached in patients with diabetes and heart failure, thus not guaranteeing the safety of the treatment. In addition, the effects evaluated in vitro do not consider the interaction of the drug with other elements of tumor microenvironment, which could result in drug effect modifications. The use of other iSGLT2 agents and their combination with therapy currently employed for CRC treatment, as radiotherapy and chemotherapy, are also to be taken into account in future investigations. Similarly, the role of DPP4 should be validated by further experimental approaches, including treatment with DDP4 inhibitors or knockout models.

Availability of data and materials

The data that support the findings of this study are available in the body of the text and supplemental materials. Raw data of this study are available at the corresponding author upon request.

Abbreviations

AMPK:

AMP-activated protein kinase

ATF6:

Activating transcription factor 6

CHOP:

C/EBP homologous protein

CRC:

Colorectal cancer

Ctr:

Control cells

DPP4:

Dipeptidyl peptidase 4

ECAR:

Extracellular acidification rate

EMT:

Epithelial-mesenchymal transition

ER:

Endoplasmic reticulum

HBSS:

Hanks’ balanced salt solution

iSGLT2:

Sodium-glucose transporter 2 inhibitors

LC3B:

Microtubule-associated protein 1 light chain 3B

NAM:

Nicotinamide

NT:

Control non-targeting siRNA

OCR:

Oxygen consumption rate

PERK:

Protein kinase RNA-like ER kinase

PI:

Propidium iodide

ROS:

Reactive oxygen species

SDS-PAGE:

Sodium dodecyl sulfate–polyacrylamide gel electrophoresis

SGLT2:

Sodium-glucose transporter 2

SIRT3:

Sirtuin 3

siSIRT3:

SIRT3 siRNA

TLR:

Toll-like receptor

References

  1. Madunić IV, Madunić J, Breljak D, Karaica D, Sabolić I. Sodium-glucose cotransporters: new targets of cancer therapy? Arh Hig Rada Toksikol. 2018;69(4):278–85.

    Article  PubMed  Google Scholar 

  2. Basak D, Gamez D, Deb S. SGLT2 inhibitors as potential anticancer agents. Biomedicines. 2023;11(7):1867.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ishikawa N, Oguri T, Isobe T, Fujitaka K, Kohno N. SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res. 2001;92:874–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci USA. 2015;112:E4111–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wright EM. SGLT2 and cancer. Pflügers Arch Eur J Physiol. 2020;472:1407–14.

    Article  CAS  Google Scholar 

  6. Fujiyoshi S, Honda S, Ara M, Kondo T, Kobayashi N, Taketomi A. SGLT2 is upregulated to acquire cisplatin resistance and SGLT2 inhibition reduces cisplatin resistance in hepatoblastoma. J Hepatobiliary Pancreat Sci. 2023

  7. Kobayashi M, Uematsu T, Tokura Y, Takei K, Sakamoto K, Narimatsu T, et al. Immunohistochemical expression of Sodium-Dependent Glucose Transporter-2 (SGLT-2) in clear cell renal carcinoma: Possible prognostic implications. Int Braz J Urol. 2019;45:169–78.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Forzano I, Wilson S, Lombardi A, Jankauskas SS, Kansakar U, Mone P, Varzideh F, Santulli G. SGLT2 inhibitors: an evidence-based update on cardiovascular implications. Expert Opin Investig Drugs. 2023;32(9):839–847.

  9. Colloca A, Donisi I, Anastasio C, Balestrieri ML, D’Onofrio N. Metabolic alteration bridging the prediabetic state and colorectal cancer. Cells. 2024;13(8):663.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23(7):3651.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12(2):78–89.

    Article  CAS  PubMed  Google Scholar 

  12. Marfella R, D’Onofrio N, Trotta MC, Sardu C, Scisciola L, Amarelli C, et al. Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts. Metabolism. 2022;127: 154936.

    Article  CAS  PubMed  Google Scholar 

  13. Santulli G, Varzideh F, Forzano I, Wilson S, Salemme L, de Donato A, Lombardi A, Rainone A, Nunziata L, Jankauskas SS, Tesorio T, Guerra G, Kansakar U, Mone P. Functional and clinical importance of SGLT2-inhibitors in frailty: from the kidney to the heart. Hypertension. 2023;80(9):1800–9.

    Article  CAS  PubMed  Google Scholar 

  14. D’Onofrio N, Sardu C, Trotta MC, Scisciola L, Turriziani F, Ferraraccio F, et al. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose co-transporter2 inhibitor treatment. Mol Metab. 2021;54: 101337.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020;19(1):98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691–704.

    Article  CAS  PubMed  Google Scholar 

  17. Ferrannini E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 2017;26(1):27–38.

    Article  CAS  PubMed  Google Scholar 

  18. Naznin F, Sakoda H, Okada T, Tsubouchi H, Waise TM, Arakawa K, Nakazato M. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. Eur J Pharmacol. 2017;794:37–44.

    Article  CAS  PubMed  Google Scholar 

  19. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941–50.

    Article  CAS  PubMed  Google Scholar 

  20. Hollander P, Bays HE, Rosenstock J, Frustaci ME, Fung A, Vercruysse F, Erondu N. Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial. Diabetes Care. 2017;40(5):632–9.

    Article  CAS  PubMed  Google Scholar 

  21. Benedetti R, Benincasa G, Glass K, Chianese U, Vietri MT, Congi R, Altucci L, Napoli C. Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. Pharmacol Res. 2022;175: 106039.

    Article  CAS  PubMed  Google Scholar 

  22. Ding L, Chen X, Zhang W, Dai X, Guo H, Pan X, Xu Y, Feng J, Yuan M, Gao X, Wang J, Xu X, Li S, Wu H, Cao J, He Q, Yang B. Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. J Clin Invest. 2023;133(1): e154754.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Saito T, Okada S, Yamada E, Shimoda Y, Osaki A, Tagaya Y, et al. Effect of dapagliflozin on colon cancer cell [Rapid Communication]. Endocr J. 2015;62(12):1133–7.

    Article  CAS  PubMed  Google Scholar 

  24. Wei Q, Qian Y, Yu J, Wong CC. Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications. Oncogene. 2020;39(39):6139–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

    Article  PubMed  Google Scholar 

  26. van den Berg I, Coebergh van den Braak RRJ, van Vugt JLA, Ijzermans JNM, Buettner S. Actual survival after resection of primary colorectal cancer: results from a prospective multicenter study. World J Surg Oncol. 2021;19(1):96.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Pakiet A, Kobiela J, Stepnowski P, Sledzinski T, Mika A. Changes in lipids composition and metabolism in colorectal cancer: a review. Lipids Health Dis. 2019;18(1):29.

    Article  PubMed  PubMed Central  Google Scholar 

  28. La Vecchia S, Sebastián C. Metabolic pathways regulating colorectal cancer initiation and progression. Semin Cell Dev Biol. 2020;98:63–70.

    Article  PubMed  Google Scholar 

  29. Park JH, Pyun WY, Park HW. Cancer metabolism: phenotype, signaling and therapeutic targets. Cells. 2020;9(10):2308.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2009;121(1):29–40.

    Article  CAS  PubMed  Google Scholar 

  31. Hawley SA, Ford RJ, Smith BK, Gowans GJ, Mancini SJ, Pitt RD, et al. The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65(9):2784–94.

    Article  CAS  PubMed  Google Scholar 

  32. Yang X, Liu Q, Li Y, Tang Q, Wu T, Chen L, et al. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway. Adipocyte. 2020;9(1):484–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Villani LA, Smith BK, Marcinko K, Ford RJ, Broadfield LA, Green AE, et al. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab. 2016;5(10):1048–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ali A, Mekhaeil B, Biziotis OD, Tsakiridis EE, Ahmadi E, Wu J, et al. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Commun Biol. 2023;6(1):919.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Biziotis OD, Tsakiridis EE, Ali A, Ahmadi E, Wu J, Wang S, et al. Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α. Mol Oncol. 2023;17(11):2235–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Wang Z, Zhai J, Zhang T, He L, Ma S, Zuo Q, et al. Canagliflozin ameliorates epithelial-mesenchymal transition in high-salt diet-induced hypertensive renal injury through restoration of sirtuin 3 expression and the reduction of oxidative stress. Biochem Biophys Res Commun. 2023;653:53–61.

    Article  CAS  PubMed  Google Scholar 

  37. D’Onofrio N, Martino E, Balestrieri A, Mele L, Neglia G, Balestrieri ML, Campanile G. SIRT3 and metabolic reprogramming mediate the antiproliferative effects of whey in human colon cancer cells. Cancers (Basel). 2021;13(20):5196.

    Article  CAS  PubMed  Google Scholar 

  38. Martino E, Balestrieri A, Mele L, Sardu C, Marfella R, D’Onofrio N, et al. Milk exosomal miR-27b worsen endoplasmic reticulum stress mediated colorectal cancer cell death. Nutrients. 2022;14(23):5081.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Martino E, Luce A, Balestrieri A, Mele L, Anastasio C, D’Onofrio N, Balestrieri ML, Campanile G. Whey improves in vitro endothelial mitochondrial function and metabolic redox status in diabetic state. Antioxidants (Basel). 2023;12(6):1311.

    Article  CAS  PubMed  Google Scholar 

  40. Martino E, Balestrieri A, Anastasio C, Maione M, Mele L, Cautela D, et al. SIRT3 modulates endothelial mitochondrial redox state during insulin resistance. Antioxidants (Basel). 2022;11(8):1611.

    Article  CAS  PubMed  Google Scholar 

  41. D’Onofrio N, Prattichizzo F, Marfella R, Sardu C, Martino E, Scisciola L, et al. SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells. Theranostics. 2023;13(2):531–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. D’Onofrio N, Martino E, Mele L, Colloca A, Maione M, Cautela D, et al. Colorectal cancer apoptosis induced by dietary δ-valerobetaine involves PINK1/Parkin dependent-mitophagy and SIRT3. Int J Mol Sci. 2021;22(15):8117.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. D’Onofrio N, Prattichizzo F, Martino E, Anastasio C, Mele L, La Grotta R, et al. MiR-27b attenuates mitochondrial oxidative stress and inflammation in endothelial cells. Redox Biol. 2023;62: 102681.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Colloca A, Balestrieri A, Anastasio C, Balestrieri ML, D’Onofrio N. Mitochondrial sirtuins in chronic degenerative diseases: new metabolic targets in colorectal cancer. Int J Mol Sci. 2022;23(6):3212.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Rocha M, Apostolova N, Diaz-Rua R, Muntane J, Victor VM. Mitochondria and T2D: role of autophagy, ER stress, and inflammasome. Trends Endocrinol Metab. 2020;31(10):725–41.

    Article  CAS  PubMed  Google Scholar 

  46. D’Onofrio N, Martino E, Balestrieri A, Mele L, Cautela D, Castaldo D, Balestrieri ML. Diet-derived ergothioneine induces necroptosis in colorectal cancer cells by activating the SIRT3/MLKL pathway. FEBS Lett. 2022;596(10):1313–29.

    Article  CAS  PubMed  Google Scholar 

  47. Gan L, Li Q, Nie W, Zhang Y, Jiang H, Tan C, et al. PROX1-mediated epigenetic silencing of SIRT3 contributes to proliferation and glucose metabolism in colorectal cancer. Int J Biol Sci. 2023;19(1):50–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Liao M, Sun X, Zheng W, Wu M, Wang Y, Yao J, et al. LINC00922 decoys SIRT3 to facilitate the metastasis of colorectal cancer through up-regulation the H3K27 crotonylation of ETS1 promoter. Mol Cancer. 2023;22(1):163.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Yang M, Xi N, Gao M, Yu Y. Sitagliptin mitigates hypoxia/reoxygenation (H/R)-induced injury in cardiomyocytes by mediating sirtuin 3 (SIRT3) and autophagy. Bioengineered. 2022;13(5):13162–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Shih JW, Wu ATH, Mokgautsi N, Wei PL, Huang YJ. Preclinical repurposing of sitagliptin as a drug candidate for colorectal cancer by targeting CD24/CTNNB1/SOX4-centered signaling hub. Int J Mol Sci. 2024;25(1):609.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Scafoglio CR, Villegas B, Abdelhady G, Bailey ST, Liu J, Shirali AS, et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med. 2018;10(467):eaat5933.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem. 2020;295(42):14379–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Zhou J, Zhu J, Yu SJ, Ma HL, Chen J, Ding XF, et al. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway. Biomed Pharmacother. 2020;132: 110821.

    Article  CAS  PubMed  Google Scholar 

  54. Nalla LV, Khairnar A. Empagliflozin mediated miR-128-3p upregulation promotes differentiation of hypoxic cancer stem-like cells in breast cancer. Eur J Pharmacol. 2023;943: 175565.

    Article  CAS  PubMed  Google Scholar 

  55. Zeng Y, Jiang H, Zhang X, Xu J, Wu X, Xu Q, et al. Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation. Free Radic Biol Med. 2023;208:571–86.

    Article  CAS  PubMed  Google Scholar 

  56. Okada J, Matsumoto S, Kaira K, Saito T, Yamada E, Yokoo H, et al. Sodium glucose cotransporter 2 inhibition combined with cetuximab significantly reduced tumor size and carcinoembryonic antigen level in colon cancer metastatic to liver. Clin Colorectal Cancer. 2018;17(1):e45-48.

    Article  PubMed  Google Scholar 

  57. Okada J, Yamada E, Saito T, Yokoo H, Osaki A, Shimoda Y, et al. Dapagliflozin inhibits cell adhesion to collagen I and IV and increases ectodomain proteolytic cleavage of DDR1 by increasing ADAM10 activity. Molecules. 2020;25(3):495.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Nasiri AR, Rodrigues MR, Li Z, Leitner BP, Perry RJ. SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia. Cancer Metab. 2019;7:10.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Kato J, Shirakami Y, Ohnishi M, Mizutani T, Kubota M, Sakai H, et al. Suppressive effects of the sodium-glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice. Oncol Rep. 2019;42(6):2797–805.

    CAS  PubMed  Google Scholar 

  60. Yamamoto L, Yamashita S, Nomiyama T, Kawanami T, Hamaguchi Y, Shigeoka T, et al. Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro. Diabetol Int. 2021;12(4):389–98.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Wang Y, Yang L, Mao L, Zhang L, Zhu Y, Xu Y, et al. SGLT2 inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways. Cancer Cell Int. 2022;22(1):74.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Jojima T, Wakamatsu S, Kase M, Iijima T, Maejima Y, Shimomura K, et al. The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma. Int J Mol Sci. 2019;20(20):5237.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Abdel-Rafei MK, Thabet NM, Rashed LA, Moustafa EM. Canagliflozin, a SGLT-2 inhibitor, relieves ER stress, modulates autophagy and induces apoptosis in irradiated HepG2 cells: Signal transduction between PI3K/AKT/GSK-3β/mTOR and Wnt/β-catenin pathways; in vitro. J Cancer Res Ther. 2021;17(6):1404–18.

    Article  CAS  PubMed  Google Scholar 

  64. Steinberg GR, Hardie DG. New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol. 2023;24(4):255–72.

    Article  CAS  PubMed  Google Scholar 

  65. Shoda K, Tsuji S, Nakamura S, Egashira Y, Enomoto Y, Nakayama N, et al. Canagliflozin inhibits glioblastoma growth and proliferation by activating AMPK. Cell Mol Neurobiol. 2023;43(2):879–92.

    Article  CAS  PubMed  Google Scholar 

  66. Malik N, Ferreira BI, Hollstein PE, Curtis SD, Trefts E, Weiser Novak S, et al. Induction of lysosomal and mitochondrial biogenesis by AMPK phosphorylation of FNIP1. Science. 2023;380(6642):eabj5559.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Lin Y, Jiang M, Chen W, Zhao T, Wei Y. Cancer and ER stress: mutual crosstalk between autophagy, oxidative stress and inflammatory response. Biomed Pharmacother. 2019;118: 109249.

    Article  CAS  PubMed  Google Scholar 

  68. Yang J, Li L, Li C, Chen W, Liu Y, Luo S, et al. PACS-2 deficiency aggravates tubular injury in diabetic kidney disease by inhibiting ER-phagy. Cell Death Dis. 2023;14(10):649.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. D’Onofrio N, Cacciola NA, Martino E, Borrelli F, Fiorino F, Lombardi A, et al. ROS-mediated apoptotic cell death of human colon cancer LoVo cells by Milk δ-Valerobetaine. Sci Rep. 2020;10(1):8978.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Celesia A, Morana O, Fiore T, Pellerito C, D’Anneo A, Lauricella M, et al. ROS-dependent ER stress and autophagy mediate the anti-tumor effects of tributyltin (IV) ferulate in colon cancer cells. Int J Mol Sci. 2020;21(21):8135.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Park GB, Jin DH, Kim D. Sequential treatment with celecoxib and bortezomib enhances the ER stress-mediated autophagy-associated cell death of colon cancer cells. Oncol Lett. 2018;16(4):4526–36.

    PubMed  PubMed Central  Google Scholar 

  72. Zhou Y, Cheng S, Chen S, Zhao Y. Prognostic and clinicopathological value of SIRT3 expression in various cancers: a systematic review and meta-analysis. Onco Targets Ther. 2018;11:2157–67.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Wan X, Wang C, Huang Z, Zhou D, Xiang S, Qi Q, et al. Cisplatin inhibits SIRT3-deacetylation MTHFD2 to disturb cellular redox balance in colorectal cancer cell. Cell Death Dis. 2020;11(8):649.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Torrens-Mas M, Hernández-López R, Pons DG, Roca P, Oliver J, Sastre-Serra J. Sirtuin 3 silencing impairs mitochondrial biogenesis and metabolism in colon cancer cells. Am J Physiol Cell Physiol. 2019;317(2):C398–404.

    Article  CAS  PubMed  Google Scholar 

  75. Li M, Chiang YL, Lyssiotis CA, Teater MR, Hong JY, Shen H, et al. Non-oncogene addiction to SIRT3 plays a critical role in lymphomagenesis. Cancer Cell. 2019;35(6):916-931.e9.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Liu Y, Wei H, Li J. A review on SIRT3 and its natural small molecule activators as a potential Preventive and therapeutic target. Eur J Pharmacol. 2024;963: 176155.

    Article  CAS  PubMed  Google Scholar 

  77. Torrens-Mas M, Oliver J, Roca P, Sastre-Serra J. SIRT3: oncogene and tumor suppressor in cancer. Cancers (Basel). 2017;9(7):90.

    Article  PubMed  Google Scholar 

  78. Wei Y, Xiao G, Xu H, Sun X, Shi Y, Wang F, et al. Radiation resistance of cancer cells caused by mitochondrial dysfunction depends on SIRT3-mediated mitophagy. FEBS J. 2023;290(14):3629–45.

    Article  CAS  PubMed  Google Scholar 

  79. Wei Z, Song J, Wang G, Cui X, Zheng J, Tang Y, et al. Deacetylation of serine hydroxymethyl-transferase 2 by SIRT3 promotes colorectal carcinogenesis. Nat Commun. 2018;9(1):4468.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Khodaei F, Hosseini SM, Omidi M, Hosseini SF, Rezaei M. Cytotoxicity of metformin against HT29 colon cancer cells contributes to mitochondrial Sirt3 upregulation. J Biochem Mol Toxicol. 2021;35(3): e22662.

    Article  CAS  PubMed  Google Scholar 

  81. Wang CY, Chen CC, Lin MH, Su HT, Ho MY, Yeh JK, et al. TLR9 binding to Beclin 1 and mitochondrial SIRT3 by a sodium-glucose co-transporter 2 inhibitor protects the heart from doxorubicin toxicity. Biology (Basel). 2020;9(11):369.

    CAS  PubMed  Google Scholar 

  82. Li J, Liu H, Takagi S, Nitta K, Kitada M, Srivastava SP, et al. Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules. JCI Insight. 2020;5(6): e129034.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Ng L, Foo DC, Wong CK, Man AT, Lo OS, Law WL. Repurposing DPP-4 inhibitors for colorectal cancer: a retrospective and single center study. Cancers (Basel). 2021;13(14):3588.

    Article  CAS  PubMed  Google Scholar 

  84. Aso Y, Kato K, Sakurai S, Kishi H, Shimizu M, Jojima T, et al. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. Int J Clin Pract. 2019;73(5): e13335.

    Article  PubMed  Google Scholar 

  85. Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi J, John A, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers (Basel). 2022;14(7):1732.

    Article  PubMed  Google Scholar 

  86. Li F, Lin Y, Li R, Shen X, Xiang M, Xiong G, et al. Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches. Front Pharmacol. 2023;14:1165666.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Patel R, Negassa A, Tolu SS, Acuna-Villaorduna A, Goel S. Effectiveness of biologic agents among hispanic patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2023;S1533–0028(23):00089.

    Google Scholar 

  88. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This research was funded by STUPORANIMA Project, Funder: Italian Ministry of Health-RC, Number: IZS ME 09/22; ENDO-CARE Project, Funder: Ministero dell’Università e della Ricerca, Next Generation EU Number: P2022SZE5Y; Fuelmilk Project, Funder: Ministero dell’Università e della Ricerca, Number: 2022KH87XS; FORMULAMI Project, Funder: Ministero dello Sviluppo Economico, Number: F/310110/04/X56.

Author information

Authors and Affiliations

  1. Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138, Naples, Italy

    Camilla Anastasio, Isabella Donisi, Antonino Colloca, Maria Luisa Balestrieri & Nunzia D’Onofrio

  2. Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Via Luciano Armanni 5, 80138, Naples, Italy

    Vitale Del Vecchio & Luigi Mele

  3. Department of Advanced Clinical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138, Naples, Italy

    Celestino Sardu & Raffaele Marfella

Authors
  1. Camilla Anastasio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Isabella Donisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vitale Del Vecchio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonino Colloca
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luigi Mele
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Celestino Sardu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Raffaele Marfella
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maria Luisa Balestrieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nunzia D’Onofrio
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization, MLB., NDO.; methodology, CA., ID., VDV.; formal analysis, CA., ID., AC.; investigation, NDO.; data curation, VDV.; writing—original draft preparation, LM., NDO.; writing—review and editing, LM., CS., RM., MLB., NDO.; supervision, RM., MLB.; project administration, MLB.; funding acquisition, MLB., NDO. All authors have read and agreed to the published version of the manuscript.

Corresponding author

Correspondence to Nunzia D’Onofrio.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anastasio, C., Donisi, I., Del Vecchio, V. et al. SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells. Cell Mol Biol Lett 29, 80 (2024). https://doi.org/10.1186/s11658-024-00599-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s11658-024-00599-1

Keywords

Cellular & Molecular Biology Letters

ISSN: 1689-1392

Contact us